LIfT successfully produces CAR-IMANs to further enhance alpha neutrophil cancer killing
LIfT BioSciences reports a substantial increase in cancer killing with the addition of a HER2 targeting CAR to its IMAN cell therapy -...
top of page
Welcome to LIfT BioSciences
LIfT BioSciences is developing a breakthrough allogeneic innate cell therapy platform called
Neutrophil Only Leukocyte Infusion Therapy (N-LIfT), that produces different types of Immunomodulatory Alpha Neutrophils (IMANs). LIfT's focus is on producing an exceptional type of anti-cancer alpha neutrophil with enhanced cytotoxic and immunomodulatory properties.
Our mission is to develop affordable curative cell therapies for solid tumours with high unmet medical need.
bottom of page